Frontline Pembrolizumab Plus Chemo Shows Promise in Ovarian Cancer
1st-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab, followed by pembrolizumab maintenance, appeared feasible and safe for patients with advanced ovarian cancer, preliminary data from a small clinical trial suggested.
Source
Leave a Reply
Want to join the discussion?Feel free to contribute!